MX2018002263A - Potenciador de atp intracelular. - Google Patents
Potenciador de atp intracelular.Info
- Publication number
- MX2018002263A MX2018002263A MX2018002263A MX2018002263A MX2018002263A MX 2018002263 A MX2018002263 A MX 2018002263A MX 2018002263 A MX2018002263 A MX 2018002263A MX 2018002263 A MX2018002263 A MX 2018002263A MX 2018002263 A MX2018002263 A MX 2018002263A
- Authority
- MX
- Mexico
- Prior art keywords
- agent
- atp
- increasing
- cells
- effect
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un problema a ser resuelto por la presente invención es proporcionar una sustancia que tenga un efecto de aumentar el ATP intracelular y, en términos particulares, un potente potenciador de ATP que supere por mucho el efecto cada vez mayor de inosina o febuxostat por sí solos. Un potenciador de ATP intracelular de origen humano o animal que comprende una combinación de A) y B): A) un inhibidor de xantina oxidasa/xantina deshidrogenasa o una sal farmacéuticamente aceptable del mismo; y B) cualquiera o cualesquiera de los compuestos seleccionados a partir de inosina, ácido inosínico, hipoxantina y sales farmacéuticamente aceptables de los mismos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015166372 | 2015-08-26 | ||
PCT/JP2016/074644 WO2017033963A1 (ja) | 2015-08-26 | 2016-08-24 | 細胞内atp増強剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018002263A true MX2018002263A (es) | 2018-03-23 |
Family
ID=58100417
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018002263A MX2018002263A (es) | 2015-08-26 | 2016-08-24 | Potenciador de atp intracelular. |
Country Status (11)
Country | Link |
---|---|
US (1) | US10682372B2 (es) |
EP (1) | EP3342414B1 (es) |
JP (2) | JP6153281B1 (es) |
KR (1) | KR102600879B1 (es) |
CN (1) | CN107921054B (es) |
BR (1) | BR112018002648B1 (es) |
CA (1) | CA2995052C (es) |
HK (1) | HK1246165A1 (es) |
MX (1) | MX2018002263A (es) |
RU (1) | RU2728722C2 (es) |
WO (1) | WO2017033963A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3054963B1 (fr) * | 2016-08-10 | 2018-09-14 | Assistance Publique-Hopitaux De Paris (Ap-Hp) | Utilisation d'un inhibiteur de la synthese de novo des purines, dans le traitement du deficit en adenylosuccinate lyase |
JP6937134B2 (ja) | 2016-11-21 | 2021-09-22 | 株式会社スタージェン | 細胞内atp増強剤 |
WO2018092911A1 (ja) * | 2016-11-21 | 2018-05-24 | 株式会社スタージェン | 細胞内atp増強剤 |
US11491175B2 (en) | 2019-02-25 | 2022-11-08 | Celagenex Research (India) Pvt. Ltd. | Synergistic bioactive compositions for enhancing cellular energy |
JP7333942B2 (ja) | 2019-06-07 | 2023-08-28 | 株式会社スタージェン | 神経変性疾患に対するatp増強療法の効果を予測する方法 |
CN110441457A (zh) * | 2019-08-02 | 2019-11-12 | 深圳市绿航星际太空科技研究院 | 一种检测尿液中同型半胱氨酸的方法 |
WO2022124325A1 (ja) | 2020-12-08 | 2022-06-16 | 国立大学法人東京大学 | 細胞内atp増強剤 |
WO2023135827A1 (ja) * | 2022-01-13 | 2023-07-20 | NeSA合同会社 | 神経変性疾患の進行遅延及び防御剤 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6440455B1 (en) | 1997-09-02 | 2002-08-27 | Children's Medical Center Corporation | Methods for modulating the axonal outgrowth of central nervous system neurons |
US8318792B2 (en) | 2006-07-19 | 2012-11-27 | Nippon Medical School Foundation | Therapeutic agent for amyotrophic lateral sclerosis |
EP2046320A2 (en) * | 2006-08-02 | 2009-04-15 | INSERM (Institut National de la Santé et de la Recherche Medicale) | Anticonvulsive pharmaceutical compositions |
EA018193B3 (ru) * | 2007-11-27 | 2014-07-30 | Ардеа Биосайнсиз Инк. | Соединения и фармацевтические композиции для снижения уровня мочевой кислоты |
WO2011022757A1 (en) * | 2009-08-24 | 2011-03-03 | Queensland University Of Technology | Purine-targeted diagnosis and therapy of wounds |
CN102106896B (zh) * | 2009-12-23 | 2012-05-30 | 昆明贝叶傣医药研究所 | 中药材土千年健在制药中的新应用 |
WO2012014117A1 (en) | 2010-07-30 | 2012-02-02 | Ranbaxy Laboratories Limited | Improved process for the preparation of febuxostat |
CA2813555C (en) * | 2010-10-15 | 2014-11-25 | Ardea Biosciences, Inc. | Methods for treating hyperuricemia and related diseases |
WO2012122532A2 (en) * | 2011-03-09 | 2012-09-13 | Biocryst Pharmaceuticals, Inc. | Compositions and methods for treatment of hyperuricemia |
CN102994537A (zh) * | 2012-11-21 | 2013-03-27 | 广东肇庆星湖生物科技股份有限公司 | 一种嘌呤核苷磷酸化酶基因敲除的大肠杆菌Ecoli-SL26的构建方法 |
-
2016
- 2016-08-24 KR KR1020187007813A patent/KR102600879B1/ko active IP Right Grant
- 2016-08-24 RU RU2018110363A patent/RU2728722C2/ru active
- 2016-08-24 EP EP16839310.6A patent/EP3342414B1/en active Active
- 2016-08-24 US US15/754,842 patent/US10682372B2/en active Active
- 2016-08-24 BR BR112018002648-4A patent/BR112018002648B1/pt active IP Right Grant
- 2016-08-24 CN CN201680049519.6A patent/CN107921054B/zh active Active
- 2016-08-24 CA CA2995052A patent/CA2995052C/en active Active
- 2016-08-24 MX MX2018002263A patent/MX2018002263A/es unknown
- 2016-08-24 WO PCT/JP2016/074644 patent/WO2017033963A1/ja active Application Filing
- 2016-08-24 JP JP2016572842A patent/JP6153281B1/ja active Active
-
2017
- 2017-05-29 JP JP2017105857A patent/JP2017141308A/ja active Pending
-
2018
- 2018-05-02 HK HK18105648.5A patent/HK1246165A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
RU2018110363A3 (es) | 2020-01-29 |
HK1246165A1 (zh) | 2018-09-07 |
EP3342414A1 (en) | 2018-07-04 |
BR112018002648B1 (pt) | 2024-01-09 |
KR102600879B1 (ko) | 2023-11-09 |
CN107921054A (zh) | 2018-04-17 |
WO2017033963A1 (ja) | 2017-03-02 |
CA2995052A1 (en) | 2017-03-02 |
EP3342414B1 (en) | 2022-04-06 |
JPWO2017033963A1 (ja) | 2017-08-24 |
BR112018002648A2 (es) | 2018-10-02 |
US20180243326A1 (en) | 2018-08-30 |
US10682372B2 (en) | 2020-06-16 |
KR20180039164A (ko) | 2018-04-17 |
CN107921054B (zh) | 2020-12-04 |
CA2995052C (en) | 2023-08-22 |
EP3342414A4 (en) | 2019-04-17 |
JP2017141308A (ja) | 2017-08-17 |
JP6153281B1 (ja) | 2017-06-28 |
RU2018110363A (ru) | 2019-09-26 |
RU2728722C2 (ru) | 2020-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018002263A (es) | Potenciador de atp intracelular. | |
EP3732180A4 (en) | COMBINED MODALITIES FOR NUCLEOSIDES AND/OR NADPH OXIDASE (NOX) INHIBITORS AS MYELOID CELL SPECIFIC ANTIVIRAL AGENTS | |
PH12020551332A1 (en) | Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors | |
IL283743A (en) | History of 2-Oxoquinazoline as Methionine Adenosyl Transferase 2a Inhibitors | |
PH12020550622A1 (en) | Kras g12c inhibitors | |
PH12018500792A1 (en) | Benzolactam compounds as protein kinase inhibitors | |
MX2018013983A (es) | Inhibidores g12c de kras. | |
MA39986A (fr) | Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer | |
CL2017001566A1 (es) | Derivados de azabiciclootano como agonistas de fxr para el uso en el tratamiento de enfermedades hepáticas y gastrointestinales. | |
BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
FI3805233T3 (fi) | N-(5-(3-hydroksipyrrolidin-1-yyli)-2-morfolinooksatsolo[4,5-b]pyridin-6-yyli)-2-(2-metylipyridin-4-yyli)okatsoli-karboksamidin (r)- (s)-enantiomeerit irak4-estäjänä syövän hoitoon | |
PH12016501567A1 (en) | 4`-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza rna replication | |
MX2020012376A (es) | Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b. | |
DK3377495T3 (da) | 2-phenyl-3,4-dihydropyrrolo[2,1-f] [1,2,4]triazinon-derivativer som phosphodiesterasehæmmere og anvendelser deraf | |
PH12019501022A1 (en) | Pyrazolopyrimidine compounds and methods of use thereof | |
MX2015015162A (es) | Agente de reduccion de acido urico. | |
BR112017000730A2 (pt) | derivados de pirrolidinona como inibidores de metap-2 | |
WO2016198698A3 (en) | P38 inhibitors for the treatment and prophylaxis of liver cancer | |
PH12015502021A1 (en) | Salt forms of (s)-quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate | |
EA201791021A1 (ru) | 1-[2-(АМИНОМЕТИЛ)БЕНЗИЛ]-2-ТИОКСО-1,2,3,5-ТЕТРАГИДРО-4H-ПИРРОЛО[3,2-d]ПИРИМИДИН-4-ОНЫ КАК ИНГИБИТОРЫ МИЕЛОПЕРОКСИДАЗЫ | |
MX2018008307A (es) | Derivado de ascoclorina y uso del mismo como activador de proteina cinasa activada por adenosin monofosfato (ampk). | |
MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
EA201890896A1 (ru) | Твердый препарат для перорального применения, содержащий аморфный солифенацин, и способ его получения | |
CL2018001408A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer | |
EA201991570A1 (ru) | Амидные соединения и их применение |